Patents Assigned to Chiesi Farmaceutici S.p.A.
-
Publication number: 20240217967Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.Type: ApplicationFiled: March 25, 2022Publication date: July 4, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Nicolò IOTTI, Keith Christopher KNIGHT, Toby Matthew Grover MULLINS, Anna KARAWAJCZYK, Ben Paul WHITTAKER
-
Publication number: 20240209001Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.Type: ApplicationFiled: March 14, 2022Publication date: June 27, 2024Applicant: CHIESI FARMACEUTICI S.P. A.Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Alberto CUZZOLIN, Milan MESIC, Dinko ZIHER, Ivaylo ELENKOV, Kristina BUTKOVIC
-
Patent number: 12016851Abstract: The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.Type: GrantFiled: April 11, 2022Date of Patent: June 25, 2024Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di MilanoInventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
-
Patent number: 12016850Abstract: The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.Type: GrantFiled: April 11, 2022Date of Patent: June 25, 2024Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di MilanoInventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
-
Publication number: 20240199635Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.Type: ApplicationFiled: March 25, 2022Publication date: June 20, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZi, Keith Christopher KNIGHT, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS, Ben Paul WHITTAKER
-
Publication number: 20240190891Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: July 14, 2021Publication date: June 13, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Claudio FIORELLI, Barbara BERTANI
-
Publication number: 20240190847Abstract: The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.Type: ApplicationFiled: March 25, 2022Publication date: June 13, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS
-
Publication number: 20240166605Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: January 2, 2024Publication date: May 23, 2024Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
-
Publication number: 20240165203Abstract: The present invention relates to a combined therapy for use in treatment and prevention of treatment and prevention of brain injury, in particular ischemic and/or hypoxic brain lesions, including but not limited to hypoxic-ischemic encephalopathy, preferably in a neonatal subject either at term or at preterm.Type: ApplicationFiled: March 25, 2022Publication date: May 23, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Bruno Pietro IMBIMBO, Gino VILLETTI, Fabrizio FACCHINETTI, Elisa LANDUCCI, Dalila MANGO
-
Publication number: 20240166651Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.Type: ApplicationFiled: March 14, 2022Publication date: May 23, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Dinko ZIHER, Milan MESIC, Ivaylo ELENKOV
-
Patent number: 11981639Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: May 6, 2022Date of Patent: May 14, 2024Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Publication number: 20240116948Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: December 20, 2021Publication date: April 11, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
-
Publication number: 20240116947Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: July 14, 2021Publication date: April 11, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Paolo RONCHI, Matteo BIAGETTI, Sara GUARIENTO, Claudio FIORELLI
-
Publication number: 20240092792Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
-
Publication number: 20240092791Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240092790Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240082223Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 14, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
-
Publication number: 20240025880Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 26, 2021Publication date: January 25, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
-
Publication number: 20240018122Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: July 14, 2021Publication date: January 18, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
-
Publication number: 20240002371Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 26, 2021Publication date: January 4, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL